Login / Signup

How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy.

James A DavisMary McGannJessica MariniHamza Hashmi
Published in: Expert review of anticancer therapy (2024)
Keyphrases
  • single cell
  • cell therapy
  • regulatory t cells
  • dendritic cells
  • multiple myeloma
  • newly diagnosed
  • mesenchymal stem cells
  • type iii
  • bone marrow